Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 PENTETREOTIDE KIT versus IODOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 PENTETREOTIDE KIT versus IODOTOPE.
INDIUM IN-111 PENTETREOTIDE KIT vs IODOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 pentetreotide binds to somatostatin receptors, particularly subtypes 2 and 5, allowing scintigraphic localization of primary and metastatic neuroendocrine tumors bearing these receptors.
Iodine-131 is taken up by the thyroid gland and emits beta particles and gamma rays, causing destruction of thyroid tissue via radiation-induced cell death.
111 MBq (3 mCi) indium In-111 pentetreotide administered intravenously over 1 minute; single dose for planar and SPECT imaging.
For thyroid ablation: 3.7-5.55 MBq (100-150 μCi) orally as a single dose. For hyperthyroidism: 185-555 MBq (5-15 mCi) orally as a single dose.
None Documented
None Documented
Terminal half-life approximately 24 hours (range 22-26 hours), allowing imaging up to 24-48 hours post-injection
Terminal half-life is approximately 120-140 days for total body iodine, but the effective half-life for therapeutic use is 8-13 days due to biological turnover in the thyroid. For diagnostic use, effective half-life is 1-2 days.
Renal: 80-90% unchanged within 24 hours; Fecal: 5-10%
Primarily renal: >90% excreted in urine as iodide. Fecal excretion is negligible (<2%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical